APOE-ɛ4 non-carriers (N= 157) | High genetic AD risk (N= 106) | |||||||||||
Aβ ratio | NfL | p-tau | ||||||||||
Causal inference methods | β | SE | p-value | q-value* | β | SE | p-value | q-value* | β | SE | p-value | q-value* |
Inverse-variance weighted | −0.007 | 0.002 | 3.26E−04 | 6.52E−04 | 13.267 | 2.604 | 3.50E−07 | 1.40E−06 | −9.186 | 4.534 | 4.28E−02 | 1.48E−01 |
Maximum likelihood | −0.007 | 0.002 | 2.19E−03 | 4.37E−03 | 13.044 | 3.312 | 8.22E−05 | 3.29E−04 | −8.932 | 4.563 | 5.03E−02 | 1.68E−01 |
Weighted median | −0.007 | 0.002 | 4.41E−03 | 8.83E−03 | 13.627 | 3.568 | 1.34E−04 | 5.37E−04 | −8.571 | 6.224 | 1.69E−01 | 3.07E−01 |
Weighted mode | −0.007 | 0.002 | 2.62E−03 | 5.24E−03 | 13.327 | 3.259 | 4.33E−05 | 1.73E−04 | −7.867 | 7.917 | 3.20E−01 | 5.38E−01 |
Sensitivity methods | p-value | p-value | p-value | |||||||||
Cochran Q, heterogeneity test | 0.412 | 0.254 | 0.921 | |||||||||
MR-PRESSO, global test | 0.602 | 0.505 | 0.911 | |||||||||
MR-Egger, intercept test | 0.170 | 0.742 | 0.543 |